Exelixis has appointed Amy Peterson as its next Executive VP, Product Development & Medical Affairs, and Chief Medical Officer. Peterson’s experience includes senior clinical development and operational roles at Genentech, Medivation, BeiGene and CytomX. She began her industry career at Genentech. After Genentech, Peterson joined Medivation, where she was part of the filing team for the initial FDA approval of enzalutamide. At BeiGene, she was the company’s Chief Medical Officer, IO. Most recently, Peterson was at CytomX, first as Executive Vice President and Chief Development Officer and then as President and Chief Operating Officer.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on EXEL:
- Exelixis price target raised to $27 from $24 at JMP Securities
- Exelixis, Ipsen announce CONTACT-02 trial met one of two primary endpoints
- DraftKings upgraded, Home Depot downgraded: Wall Street’s top analyst calls
- SVB Securities starts Exelixis with a Market Perform, $18 price target
- Exelixis initiated with a Market Perform at SVB Securities